FTREFortrea Holdings Inc.

$851M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$701M+3.9% YoY

Gross Profit

$103M14.7% margin

Operating Income

-$16M-2.3% margin

Net Income

-$16M-2.3% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

-1.3%

Cash Flow

Operating Cash Flow

$87M

Free Cash Flow

$80M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$2.7B

Total Liabilities

$2.2B

Stockholders' Equity

$581M

Cash & Equivalents

$131M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$701M	$675M	+3.9%
Gross Profit	$103M	$148M	-30.5%
Operating Income	-$16M	-$18M	+11.7%
Net Income	-$16M	-$28M	+43.0%

Revenue Segments

Clinical Services Segment

$701M100%

Geographic Segments

North America

$333M47%

Europe

$213M30%

Other Geographical Areas

$155M22%

FTRE Q3 2025 Earnings — Fortrea Holdings Inc. Revenue & Financial Results | Market Cap Arena